Healthcare Sales & Marketing Network News: tenofovir disoproxil

Searching News Database: tenofovir disoproxil

HSMN NewsFeed - 3 Nov 2021
Antios Therapeutics Raises $75 Million in a Series B-1 Funding to Advance Clinical Programs for HBV
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 19 Sep 2019
CASI Pharmaceuticals Announces the Promotion of Larry Zhang to President
Biopharmaceuticals Personnel

HSMN NewsFeed - 12 Aug 2019
CASI Pharmaceuticals Announces Launch of EVOMELA(R) (melphalan for injection) in China
Biopharmaceuticals Oncology Product Launch

HSMN NewsFeed - 28 Mar 2018
Mylan Introduces Symfi(TM) Triple Combo Once-Daily HIV Treatment in the U.S.
Biopharmaceuticals HIV/AIDS FDA Product Launch

HSMN NewsFeed - 2 Mar 2018
Mylan to Introduce Two New Cost-Saving HIV Combination Treatments in the U.S.
Biopharmaceuticals HIV/AIDS Product Launch

HSMN NewsFeed - 10 Aug 2017
Mylan Advances Access in the Fight Against HIV with the Launch of Three Generic Antiretroviral Medicines in Canada
Biopharmaceuticals Generics Product Launch

HSMN NewsFeed - 19 May 2017
Merck Receives CHMP Positive Opinion Recommending Approval of ISENTRESS(R) (raltegravir) 600 mg in the European Union
Biopharmaceuticals Regulatory

HSMN NewsFeed - 31 Jan 2014
Mylan Named as Gilead's Exclusive Branded Medicines Business Partner for India
Biopharmaceuticals Distribution

HSMN NewsFeed - 3 May 2013
Bristol-Myers Squibb Receives US FDA sNDA Approval for Use of SUSTIVA(R) (efavirenz) in HIV-1 Infected Pediatric Patients
Biopharmaceuticals HIV/AIDS FDA

HSMN NewsFeed - 20 Sep 2011
Mylan's Matrix Receives Tentative FDA Approval Through PEPFAR for Novel "Co-Packaged" Version of HIV/AIDS Treatment
Biopharmaceuticals HIV/AIDS FDA

HSMN NewsFeed - 3 Sep 2010
Gilead Sciences Submits European Marketing Application for Once-Daily Single-Tablet Regimen of Truvada(R) and TMC278 for the Treatment of HIV Infection
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 16 Sep 2009
Mylan's Matrix Receives Tentative FDA Approval Under PEPFAR for Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate Tablets
Biopharmaceuticals HIV/AIDS FDA

HSMN NewsFeed - 18 Aug 2009
Mylan's Matrix Receives First and Only Tentative FDA Approval Under PEPFAR for Generic Version of Atripla(R) HIV Treatment
Biopharmaceuticals Generics FDA

HSMN NewsFeed - 30 Mar 2009
Mylan's Matrix Receives First Tentative FDA Approval Under PEPFAR for Generic Truvada(R)
Biopharmaceuticals Generics FDA

HSMN NewsFeed - 11 Aug 2008
U.S. Food and Drug Administration Approves Viread(R) for Chronic Hepatitis B in Adults
Biopharmaceuticals FDA

HSMN NewsFeed - 5 Aug 2008
Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 5 Aug 2008
CASTLE Data Showed Boosted REYATAZ(R) (atazanavir sulfate) and Lopinavir/r Achieved Similar Results for Undetectable Viral Load in Treatment-Naive HIV-1 Infected Patients, Regardless of Gender
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 1 Aug 2008
Gilead Sciences and Merck & Co., Inc. Enter Into an Agreement to Register and Distribute HIV Medication Atripla(R) (Efavirenz 600 mg/ Emtricitabine 200 mg/ Tenofovir Disoproxil Fumarate 300 mg) in Twelve Countries
Biopharmaceuticals HIV/AIDS Distribution

HSMN NewsFeed - 24 Jun 2008
European Commission Approves REYATAZ(R) (Atazanavir Sulfate 100mg, 150mg, 200mg, 300mg), in Combination With Other Antiretroviral Medicinal Products, for use in Treatment Naïve HIV-1 Infected Adults
Biopharmaceuticals HIV/AIDS Regulatory

HSMN NewsFeed - 25 Apr 2008
European Commission Approves Viread(R) for Chronic Hepatitis B
Biopharmaceuticals Regulatory

HSMN NewsFeed - 6 Feb 2008
CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 11 Dec 2007
Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 4 Dec 2007
Mylan Announces Tentative FDA Approval Under PEPFAR for Tenofovir Disoproxil Fumarate Tablets
Biopharmaceuticals HIV/AIDS Generics FDA

HSMN NewsFeed - 2 Nov 2007
Gilead Announces 48-Week Data from Two Pivotal Phase III Studies Evaluating Viread(R) For the Treatment of Chronic Hepatitis B
Biopharmaceuticals

HSMN NewsFeed - 29 Oct 2007
Gilead Announces 48-Week Data Evaluating Switching from Combivir(R) To Truvada(R) Among Virologically-Suppressed HIV Patients
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 18 Oct 2007
European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg)
Biopharmaceuticals HIV/AIDS Regulatory

HSMN NewsFeed - 17 Oct 2007
Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
Biopharmaceuticals Regulatory HIV/AIDS

HSMN NewsFeed - 18 Sep 2007
New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 23 Jul 2007
144-Week Data from Gilead's Study 934 Comparing Truvada(R) to Combivir(R) Both in Combination with Sustiva(R) Presented At International AIDS Society Meeting in Sydney
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 25 Jun 2007
Second Phase III Study Evaluating Gilead's Viread(R) for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
Biopharmaceuticals

HSMN NewsFeed - 6 Jun 2007
Phase III Study Evaluating Gilead's Viread(R) for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
Biopharmaceuticals

HSMN NewsFeed - 17 May 2007
Health Canada approves REYATAZ(R) (atazanavir sulfate) 300 mg single capsule formulation in combination therapy for adults with HIV-1 infection
Biopharmaceuticals HIV/AIDS Regulatory

HSMN NewsFeed - 16 Feb 2007
Merck & Co., Inc. (1) To Distribute ATRIPLA(TM) in Developing Countries
Biopharmacetuicals HIV/AIDS

HSMN NewsFeed - 15 Dec 2006
96-Week Data From Gilead's Study 934 Comparing Viread(R) and Emtriva(R) to Combivir(R) Both in Combination With Sustiva(R) Published in Journal of Acquired Immune Deficiency Syndrome
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 20 Oct 2006
FDA Approves REYATAZ(R) (atazanavir sulfate) 300 mg Single Capsule Formulation in Combination Therapy for Adults With HIV-1 Infection
Biopharmaceuticals HIV/AIDS FDA

HSMN NewsFeed - 9 Oct 2006
Bristol-Myers Squibb, Gilead Sciences and Merck & Co. Submit Marketing Authorisation Application for ATRIPLA(TM) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) to European Medicines Agency
Biopharmaceuticals Regulatory HIV/AIDS

HSMN NewsFeed - 29 Sep 2006
Bristol-Myers Squibb and Gilead Sciences establish agreement to commercialize ATRIPLA(TM) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Canada
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 28 Sep 2006
Bristol-Myers Squibb and Gilead Sciences Establish Agreement to Commercialize ATRIPLA(TM) (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg) in Canada
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 12 Jul 2006
U.S. Food and Drug Administration (FDA) Approves ATRIPLA(TM) (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), The First Once-Daily Single Tablet Regimen for Adults with HIV-1 Infection
Biopharmaceuticals FDA HIV/AIDS

Return to NewsFeed

Additional items found! 31

Members: click here for search results from The HSMN Archive (password required)

Members Archive contains 31 additional stories matching:
tenofovir disoproxil
(Password required)

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.

FindReps - available on the Apple App Store for iPhone and iPad.